Page last updated: 2024-12-05

ethacrynic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ethacrynic acid is a potent loop diuretic used to treat edema associated with heart failure, cirrhosis, and kidney disease. Its synthesis involves a multi-step process starting from 2-chloro-4-nitrobenzoic acid. It acts by inhibiting the sodium-potassium-chloride cotransporter in the ascending limb of the loop of Henle, leading to increased excretion of water, sodium, potassium, and chloride. Ethacrynic acid is also known for its anti-inflammatory and anti-cancer properties, and is under investigation for its potential use in treating various conditions. Its rapid onset of action and potent diuretic effect make it a valuable tool for managing fluid overload. Studies on ethacrynic acid focus on its efficacy and safety, as well as exploring its potential applications in other diseases.'

Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3278
CHEMBL ID456
CHEBI ID4876
SCHEMBL ID26353
MeSH IDM0007812

Synonyms (194)

Synonym
AB00051988-19
BRD-K63630713-001-05-0
AKOS003404732
nsc-624008
ethacrynic acid
nsc624008
acetic acid, [2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]-
2-[2,3-dichloro-4-(2-methylenebutanoyl)phenoxy]acetic acid
smr000058600
DIVK1C_000900
KBIO1_000900
NCI60_041898
SPECTRUM_000813
BSPBIO_002010
etacrynic acid
PRESTWICK_671
cas-58-54-8
NCGC00016260-01
SPECTRUM5_000680
acide etacrynique
CHEBI:4876 ,
acidum etacrynicum
[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
acido etacrinico
wln: qv1or bg cg dvy2&u1
2,3-dichloro-4-(2-methylenebutyl)phenoxyacetic acid
taladren
mk 595
edecrin
[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetic acid
methylenebutyrylphenoxyacetic acid
mls002701928 ,
nsc85791
58-54-8
crinuryl
mk-595
ethacrynate ,
acetic acid,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]-
hydromedin
reomax
nsc-85791
otacril
edecrina
[2,3-dichloro-4-(2-methylenebutyryl)phenoxy]acetic acid
2,3-dichloro-4-(2-methylenebutyryl)phenoxyacetic acid
acetic acid,3-dichloro-4-(2-methylenebutyryl)phenoxy]-
endecril
uregit
etakrinic acid
hidromedin
mingit
[4-(2-methylenebutyryl)-2,3-dichlorophenoxy]acetic acid
edecril
etacrinic acid
PRESTWICK2_000259
BSPBIO_000078
PRESTWICK3_000259
IDI1_000900
BPBIO1_000086
NCGC00022601-03
AB00051988
hsdb 2136
ccris 4638
nsc 624008
nsc 85791
methylenebutyryl phenoxyacetic acid
ethacrinique (acide)
kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova [czech]
brn 1915060
einecs 200-384-1
acido etacrinico [inn-spanish]
(2,3-dichloro-4-(2-methylenebutyryl)phenoxy)acetic acid
acide etacrynique [inn-french]
ethacrynic acid [usan:ban]
(4-(2-methylenebutyryl)-2,3-dichlorophenoxy)acetic acid
acetic acid, (2,3-dichloro-4-(2-methylenebutyryl)phenoxy)-
acidum etacrynicum [inn-latin]
2,3-dichloro-4-(2-methylenebutyryl)phenoxy acetic acid
acetic acid, (2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy)-
kyselina ethakrynova [czech]
1GSF
(2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid
2GSS
DB00903
etacrynic acid (jp17/inn)
D00313
ethacrynic acid (usp)
NCGC00022601-05
NCGC00022601-04
MLS000069535 ,
KBIOSS_001293
KBIO2_001293
KBIOGR_001207
KBIO2_006429
KBIO3_001230
KBIO2_003861
PRESTWICK1_000259
SPBIO_002297
SPECTRUM2_000097
SPBIO_000054
SPECTRUM4_000544
NINDS_000900
SPECTRUM3_000425
PRESTWICK0_000259
SPECTRUM1500287
[2,3-dichloro-4-(2-methylenebutanoyl)phenoxy]acetic acid
NCGC00016260-02
HMS2091D17
HMS2089N17
bdbm50186231
BMSE000134
CHEMBL456 ,
HMS502M22
e0526 ,
HMS1568D20
HMS1920M16
2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
NCGC00016260-05
A831918
HMS2095D20
HMS3259G03
tox21_201102
NCGC00258654-01
nsc-757026
nsc757026
MLS002548854
pharmakon1600-01500287
dtxsid3025257 ,
dtxcid205257
tox21_110335
CCG-38915
NCGC00016260-04
NCGC00016260-08
NCGC00016260-06
NCGC00016260-10
NCGC00016260-11
NCGC00016260-07
NCGC00016260-03
NCGC00016260-09
ethacryinic acid
kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova
ethacrynic acid [usan:usp]
unii-m5dp350vzv
etacrynic acid [inn]
kyselina ethakrynova
m5dp350vzv ,
2,3-dichloro-4-(2-methylenebutyryl)phenoxy)acetate
etacrynic acid [who-dd]
etacrynic acid [ep impurity]
etacrynic acid [mart.]
ethacrynic acid [mi]
ethacrynic acid [hsdb]
ethacrynic acid [usan]
ethacrynic acid [usp monograph]
2-(2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid
etacrynic acid [ep monograph]
etacrynic acid [jan]
4-(methylenebutyryl)-2,3-dichlorophenoxy)acetic acid
ethacrynic acid [orange book]
ethacrynic acid [vandf]
S5561
gtpl7179
2-(2,3-dichloro-4-(2-methylenebutanoyl)phenoxy)acetic acid
NC00450
SCHEMBL26353
NCGC00016260-13
tox21_110335_1
crinuril
acetic acid, [2,3-dichloro-4-(2-methylenebutyryl)phenoxy]-
[2,3-dichloro-4-(2-ethylacryloyl)phenoxy]acetic acid #
AB00051988_20
OPERA_ID_61
mfcd00056693
sr-01000003010
SR-01000003010-2
ethacrynic acid, united states pharmacopeia (usp) reference standard
ethacrynic acid, european pharmacopoeia (ep) reference standard
KS-1453
ethacrynic acid, >=97% (hplc)
etacrynic acid for system suitability, european pharmacopoeia (ep) reference standard
etacrynsaure
SR-01000003010-3
SBI-0051374.P003
HMS3712D20
CS-0013591
Q418571
etacrynicacid
HY-B1640
BRD-K63630713-001-15-9
A51097
etacrynic-acid
58-54-8 (free acid)
gst inhibitor-2 (ethacrynic acid))
Z1590781983

Research Excerpts

Overview

Ethacrynic acid (EA) is a loop diuretic that is approved orally and parenterally to manage edema-associated diseases. It inhibits Na-K-2Cl cotransporter (NKCC2) present in the thick ascending loop of Henle and muculo dens.

ExcerptReferenceRelevance
"Ethacrynic acid (EA) is a glutathione S-transferase P1-1 (GST P1-1) inhibitor with weak antiproliferative ability in tumor cells. "( Novel oxadiazole analogues derived from ethacrynic acid: design, synthesis, and structure-activity relationships in inhibiting the activity of glutathione S-transferase P1-1 and cancer cell proliferation.
Jing, Y; Li, C; Li, H; Liang, W; Liu, B; Liu, G; Song, D; Wang, R; Yang, X; Zhang, Y; Zhao, G, 2010
)
2.07
"Ethacrynic acid (EA) is a weak GSTpi inhibitor."( The synthesis of ethacrynic acid thiazole derivatives as glutathione S-transferase pi inhibitors.
Jing, Y; Li, H; Li, T; Liu, G; Yang, X; Zhao, G, 2012
)
1.44
"Ethacrynic acid (EA) is a loop diuretic that is approved orally and parenterally to manage edema-associated diseases. "( Ethacrynic acid is an inhibitor of human factor XIIIa.
Al-Horani, RA; Kar, S; Mottamal, M; Vu, K, 2022
)
3.61
"Ethacrynic acid (ECA) is a loop diuretic that inhibits the EMT process in lung cancer cells."( Ethacrynic acid suppresses B7-H4 expression involved in epithelial-mesenchymal transition of lung adenocarcinoma cells via inhibiting STAT3 pathway.
Bae Rho, S; Hoon Lee, C; Huy Phùng, H; Hyeon Kim, Y; Ji Kim, E; Ji Kim, H; Jin Kang, G; Jung Byun, H; Kim, B; Kyung Han, H; Kyung Park, M; Lee, H; Lee, K; Minh Nguyen, T; Rahman, M; Yu, L; Yun Jang, J, 2023
)
3.07
"Ethacrynic acid (ECA) is a diuretic that inhibits Na-K-2Cl cotransporter (NKCC2) present in the thick ascending loop of Henle and muculo dens and is clinically used for the treatment of edema caused by excessive body fluid. "( Ethacrynic Acid: A Promising Candidate for Drug Repurposing as an Anticancer Agent.
Lee, CH; Lee, H; Park, MK; Rho, SB; Yu, L, 2023
)
3.8
"Ethacrynic acid (ECA) is a diuretic that inhibits cellular ion flux and exerts anticancer effects."( Ethacrynic acid, a loop diuretic, suppresses epithelial-mesenchymal transition of A549 lung cancer cells via blocking of NDP-induced WNT signaling.
Byun, HJ; Kang, GJ; Kim, B; Kim, EJ; Kim, HJ; Kim, JH; Kim, SY; Lee, CH; Lee, H; Nguyen, MT; Park, MK; Rho, SB; Yu, L, 2021
)
2.79
"Ethacrynic acid (EA) is a diuretic drug that is widely used to treat high-blood pressure and swelling caused by congestive heart failure or kidney failure. "( Chemoproteomic Profiling Reveals Ethacrynic Acid Targets Adenine Nucleotide Translocases to Impair Mitochondrial Function.
Chen, X; Lei, X; Song, T; Wang, C; Ye, Z; Zhang, X; Zhu, Y, 2018
)
2.2
"Ethacrynic acid is a potential alternative to furosemide for patients with severe sulfonamide reactions."( Diuretic Renal Scintigraphy in Patients with Sulfonamide Allergies: Possible Alternative Use of Ethacrynic Acid.
Nguyen, BD; Osborn, HH; Roarke, MC; Yang, M; Young, JR, 2015
)
2.08
"Ethacrynic acid (EA) is an FDA approved drug that may have antitumor effects and may enhance the cytotoxicity of chemotherapeutic agents by binding to glutathione and inhibiting WNT signaling."( Ethacrynic acid improves the antitumor effects of irreversible epidermal growth factor receptor tyrosine kinase inhibitors in breast cancer.
Chen, T; Gao, N; Hu, Y; Huang, X; Jia, T; Jin, G; Jin, Z; Liu, B; Peng, B; Wang, Z; Zhang, N, 2016
)
2.6
"Ethacrynic acid (Edecrin) is a loop diuretic that produces a prompt and profound diuresis. "( The clinical pharmacology of ethacrynic acid.
Molnar, J; Somberg, JC,
)
1.87
"Ethacrynic acid (ECA) is a potential trabecular meshwork (TM) drug that has shown promising results in preclinical studies for treatment of primary open-angle glaucoma. "( Cellular pharmacokinetic and pharmacodynamic analyses of ethacrynic acid: Implications in topical drug delivery in the eye.
Gonzalez, P; Lin, CW; Yuan, F, 2011
)
2.06
"Ethacrynic acid is a loop diuretic little used today because of its side-effect profile and the availability of multiple alternative agents. "( Ethacrynic acid can be effective for refractory congestive heart failure and ascites.
Alisky, JM; Tuttle, TF, 2003
)
3.2
"Ethacrynic acid (ECA) is a potential glaucoma drug that can reduce intraocular pressure. "( Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment.
Challa, P; Epstein, DL; Wang, Y; Yuan, F, 2004
)
2.08
"Ethacrynic acid (EA) is a glutathione-s-transferase pi (GSTP1-1) inhibitor. "( Synthesis and structure-activity relationship of ethacrynic acid analogues on glutathione-s-transferase P1-1 activity inhibition.
Jing, Y; Wang, R; Wang, X; Yu, T; Zhao, G, 2005
)
2.03
"Ethacrynic acid (EA) is an inhibitor of rat and human GSTs."( Hepatocytes isolated from preneoplastic rat livers are resistant to ethacrynic acid cytotoxicity.
Alvarez, Mde L; Carnovale, C; Carrillo, MC; Francés, D; Parody, JP; Quiroga, A; Ronco, MT, 2007
)
1.3
"Ethacrynic acid is an inhibitor of Ca2+-Mg2+-activated ATPases which also inhibits histamine release. "( Effect of sulfhydryl-reactive ATPase inhibitors upon mast cell and basophil activation.
Cragoe, EJ; Hurtado, I; Magro, AM; Rudofsky, UH, 1983
)
1.71
"Ethacrynic acid is a well known diuretic drug. "( Antimicrotubular effects of ethacrynic acid.
Brunet, C; Cazin, M; Delacourte, A; Lesieur, D; Luyckx, M; Mallevais, ML, 1984
)
2
"Ethacrynic acid is a potent oral diuretic and saluretic agent. "( Electrophysiologic properties of ethacrynic acid in man.
Abdou, O; Chandy, F; Gopalaswamy, C; Gould, L, 1983
)
1.99
"Ethacrynic acid (EA) is a plant phenolic acid that is both an inhibitor and an inducer of glutathione S-transferase (GST) activity. "( Influence of ethacrynic acid on glutathione S-transferase pi transcript and protein half-lives in human colon cancer cells.
Kuzmich, S; Ranganathan, S; Shen, H; Tew, KD, 1995
)
2.1
"Ethacrynic acid (EA) is an inhibitor of the glutathione S-transferases (GSTs), a family of detoxification enzymes the expression of which has been associated with resistance to several classes of anticancer drugs. "( Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer.
Brennan, JM; Comis, RL; Lacreta, FP; Nash, SL; O'Dwyer, PJ; Tew, KD, 1994
)
1.99
"Ethacrynic acid is a diuretic agent that reacts with sulfhydryl groups in proteins, and which shows promise of effectiveness in the treatment of glaucoma. "( Interaction of ethacrynic acid with bovine brain tubulin.
Epstein, DL; Ludueña, RF; Roach, MC, 1994
)
2.08
"Ethacrynic acid is a glutathione S-transferase inhibitor and also undergoes conjugation with glutathione."( Sensitization to the cytotoxicity of melphalan by ethacrynic acid and hyperthermia in drug-sensitive and multidrug-resistant Chinese hamster ovary cells.
Averill-Bates, DA; Turcotte, S, 2001
)
1.29
"Ethacrynic acid (ECA) is a sulfhydryl reactive diuretic drug. "( Ethacrynic acid inhibition of microtubule assembly in vitro.
Epstein, DL; Gaskin, F; Roychowdhury, S; Xu, S, 1992
)
3.17

Effects

Ethacrynic acid has been proven to bind human albumin either covalently and non-covalently. It has ototoxic effect that occasionally results in temporally or permanent deafness.

ExcerptReferenceRelevance
"Ethacrynic acid has ototoxic effect that occasionally results in temporally or permanent deafness."( The clinical pharmacology of ethacrynic acid.
Molnar, J; Somberg, JC,
)
1.14
"Ethacrynic acid has been used as a safe and effective diuretic for more than 30 years. "( Ethacrynic acid inhibits multiple steps in the NF-kappaB signaling pathway.
Delude, RL; Englert, JA; Fink, MP; Han, Y, 2005
)
3.21
"Ethacrynic acid (ECA) has been shown to increase facility of aqueous outflow in whole eyes and perfused anterior segments, to open up spaces between cells in the trabecular meshwork and inner wall of Schlemm's canal, and to cause separation and retraction of trabecular meshwork and endothelial cells in culture. "( Ethacrynic acid disrupts steady state microtubules in vitro.
Epstein, DL; Lee, RE; O'Brien, ET, 1996
)
3.18
"Ethacrynic acid has been proven to bind human albumin either covalently and non-covalently."( Chemical modification of human albumin at cys34 by ethacrynic acid: structural characterisation and binding properties.
Bertucci, C; Nanni, B; Raffaelli, A; Salvadori, P, 1998
)
1.27
"Ethacrynic acid (EA) has been reported to reduce cholera toxin-induced intestinal fluid secretion in the intact animal. "( Reversal of cyclic AMP-mediated intestinal secretion by ethacrynic acid.
al-Awqati, Q; Field, M; Greenough, WB, 1974
)
1.94

Actions

Ethacrynic acid inhibit pancreatic exocrine secretion by depletion of glutathione and down-regulation of caerulein-induced Ca2+ mobilization. It also increases cisplatin cytotoxicity in resistant COS31 (COS31/rCDDP) cells.

ExcerptReferenceRelevance
"Ethacrynic acid, however, did inhibit substantially formation of the beta s cross-link at this concentration and half-maximally inhibited it at approximately 185 microM."( Interaction of ethacrynic acid with bovine brain tubulin.
Epstein, DL; Ludueña, RF; Roach, MC, 1994
)
1.36
"Ethacrynic acid was found to inhibit GST enzymatic activity and increase cisplatin cytotoxicity in resistant COS31 (COS31/rCDDP) cells."( In vitro reversal of glutathione-S-transferase-mediated resistance in canine osteosarcoma (COS31) cells.
Barnhill, MA; Hahn, KA; Shoieb, AM; Van Laack, RL,
)
0.85
"Ethacrynic acid inhibit pancreatic exocrine secretion by depletion of glutathione and down-regulation of caerulein-induced Ca2+ mobilization. "( Ethacrynic acid inhibits pancreatic exocrine secretion.
Klonowski-Stumpe, H; Yu, HG, 2001
)
3.2

Treatment

Treatment with ethacrynic acid or T.199 had no effect on the mRNA levels of the glutathione-dependent glyoxalase I gene. Pretreatment was followed by an increase in the renal excretion of PAH in 33-, 55, 105 and 240-day-old rats.

ExcerptReferenceRelevance
"Ethacrynic acid treatment for up to 2 h is found to cause novel shape changes and redistribution of mitochondria, as assessed by immunofluorescence and electron microscopy."( Changes in mitochondrial shape and distribution induced by ethacrynic acid and the transient formation of a mitochondrial reticulum.
Gupta, RS; Soltys, BJ, 1994
)
1.25
"Treatment with ethacrynic acid or T.199 had no effect on the mRNA levels of the glutathione-dependent glyoxalase I gene."( Modulation of detoxification gene expression in human colon HT29 cells by glutathione-S-transferase inhibitors.
Ciaccio, PJ; Jaiswal, AK; Lyttle, MH; Shen, H; Tew, KD, 1995
)
0.63
"Pretreatment with ethacrynic acid was followed by an increase in the renal excretion of PAH in 33-, 55-, 105- and 240-day-old rats but not in newborn rats."( Stimulation of renal tubular transport by ethacrynic acid in rats of different ages.
Bräunlich, H; Kangas, L, 1979
)
0.85

Toxicity

Ticrynafen, indacrinone, ethacrynic acid and A-49816, an investigational compound, were found to be toxic in hepatocyte cultures. With the exception of indacinone, paralleling the experience in humans.

ExcerptReferenceRelevance
"3 microM, ethacrynic acid was toxic to 8 of 24 (33%) tumor specimens studied."( Enhancement of anthracycline and alkylator cytotoxicity by ethacrynic acid in primary cultures of human tissues.
Kern, DH; Messenger, JC; Nagourney, RA; Weisenthal, LM, 1990
)
0.92
" Ticrynafen, indacrinone, ethacrynic acid and A-49816, an investigational compound, were found to be toxic in hepatocyte cultures; thus, with the exception of indacrinone, paralleling the experience in humans."( Toxicity of uricosuric diuretics in rat hepatocyte culture.
el Masry, S; Gray, PD; Janicki, RS; Luther, RR; Tolman, KG, 1989
)
0.58
" Preexposure of daphnids to CDNB or PCP increased the organisms' tolerance to the toxic effects of PCP, but not CDNB."( Modulation of substrate-specific glutathione S-transferase activity in Daphnia magna with concomitant effects on toxicity tolerance.
Cochrane, BJ; LeBlanc, GA, 1985
)
0.27
"Chloramphenicol is not ototoxic if administered for systemic effect, but topical applications of it to the middle ear produce severe cochlear toxic effects."( Comparative ototoxicity of chloramphenicol and kanamycin with ethacrynic acid.
Asakuma, S; Beaugard, ME; Snow, JB, 1981
)
0.5
"Glutathione (GSH) and glutathione S-transferases (GSTs) play an important role in the protection of cells against toxic effects of many electrophilic drugs and chemicals."( Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
Chen, G; Waxman, DJ, 1994
)
0.29
" Therefore, studies in diet-restricted animals may be more appropriated than studies in healthy animals for an assessment of potential adverse therapeutic side effects."( A sensitive animal model to assess acute and chronic ototoxic effects.
Lautermann, J; Schacht, J, 1996
)
0.29
" We investigated a new strategy to overcome multidrug resistance, using purified bovine serum amine oxidase, which generates two major toxic products from the polyamine spermine."( Amine oxidase, spermine, and hyperthermia induce cytotoxicity in P-glycoprotein overexpressing multidrug resistant Chinese hamster ovary cells.
Agostinelli, E; Averill-Bates, DA; Lord-Fontaine, S; Przybytkowski, E, 2001
)
0.31
" Our results showed a resistance to the toxic effects of EA since viability and cellular integrity values were significantly higher than control."( Hepatocytes isolated from preneoplastic rat livers are resistant to ethacrynic acid cytotoxicity.
Alvarez, Mde L; Carnovale, C; Carrillo, MC; Francés, D; Parody, JP; Quiroga, A; Ronco, MT, 2007
)
0.58
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"The model consisted of a cellular pharmacokinetic (PK) module to determine intracellular concentration of ECA, and a pharmacodynamic (PD) module to determine the cytotoxicity of ECA."( Cellular pharmacokinetic and pharmacodynamic analyses of ethacrynic acid: Implications in topical drug delivery in the eye.
Gonzalez, P; Lin, CW; Yuan, F, 2011
)
0.61

Compound-Compound Interactions

ExcerptReferenceRelevance
" For the continuous recording of glutamate, the microdialysis technique combined with an enzyme-linked fluorometric assay was used."( A role of glutamate in drug-induced ototoxicity: in vivo microdialysis study combined with on-line enzyme fluorometric detection of glutamate in the guinea pig cochlea.
Haruta, A; Kato, E; Komune, S; Matsuda, K; Tono, T; Yamasaki, M, 2000
)
0.31
" Patients undergoing hematopoietic stem cell transplantation (HSCT) are exposed to various types of drugs, and understanding how these drugs interact is of the utmost importance."( Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions.
Andersson, BS; Hassan, M; Valdez, BC, 2017
)
0.46
" Veverimer is not systemically absorbed, so potential drug-drug interactions (DDIs) are limited to effects on the absorption of other oral drugs through binding to veverimer in the gastrointestinal tract or increases in gastric pH caused by veverimer binding to hydrochloric acid."( Assessment of the Potential for Veverimer Drug-Drug Interactions.
Biyani, K; Guttendorf, R; Klaerner, G; Lee, A; Li, E; Mathur, V; Parsell, D; Shao, J; Stasiv, Y; Tabakman, S; Tsao, L; Wu, YS, 2021
)
0.62

Bioavailability

Ethacrynic acid (ECA) is a clinically useful ocular hypotensive for the treatment of glaucoma. The bioavailability of ECA approximates 100%. maximal blood level between 40 and 92 minutes.

ExcerptReferenceRelevance
" It is well absorbed orally."( [Long-range therapy of hypertension].
Radó, J; Szám, I; Takó, J, 1976
)
0.26
" The degree of inhibition of oedema development was quite similar after oral and intravenous administration, respectively, thus the bioavailability of clobenoside should be good."( [Edema-protective effect of clobenoside].
Felix, W; Hennings, G; Ruppert, R, 1985
)
0.27
" In humans, the relative bioavailability of oral dexketoprofen trometamol (12."( Preclinical and clinical development of dexketoprofen.
Artigas, R; Carganico, G; García, ML; Mauleón, D, 1996
)
0.29
" On the other hand, the liberation and thereby the bioavailability of poorly-soluble ethacrynic acid needs to be enhanced, and for this purpose solubility-increasing additives new to rectal therapy were used."( Solutol and cremophor products as new additives in suppository formulation.
Berkó, S; Erös, I; Regdon, G, 2002
)
0.54
" The bioavailability of ethacrynic acid approximates 100%, with maximal blood level between 40 and 92 minutes."( The clinical pharmacology of ethacrynic acid.
Molnar, J; Somberg, JC,
)
0.73
"Poor topical bioavailability and ocular irritation have impeded the development of the diuretic, ethacrynic acid (ECA) as a clinically useful ocular hypotensive for the treatment of glaucoma."( Eyedrops containing SA9000 prodrugs result in sustained reductions in intraocular pressure in rabbits.
Arnold, JJ; Challa, P; Chen, X; Choksi, Y; Epstein, DL; Hatten, J; Shimazaki, A; Toone, EJ, 2009
)
0.57
"These data suggest that novel thiol donor adduction can improve the ocular bioavailability and tolerability of SA9000."( Eyedrops containing SA9000 prodrugs result in sustained reductions in intraocular pressure in rabbits.
Arnold, JJ; Challa, P; Chen, X; Choksi, Y; Epstein, DL; Hatten, J; Shimazaki, A; Toone, EJ, 2009
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, its clinical use is limited due to its low bioavailability and side effects, such as liver damage and hearing loss at high doses."( Ethacrynic Acid: A Promising Candidate for Drug Repurposing as an Anticancer Agent.
Lee, CH; Lee, H; Park, MK; Rho, SB; Yu, L, 2023
)
2.35

Dosage Studied

The dosage range of ethacrynic acid during which the interaction occurs is very narrow, while the dose range of kanamycin is very large. After dosing horses intravenously with 5 mg ethacynic acid per horse, the parent drug or its metabolites are detec.

ExcerptRelevanceReference
"Effects of dihydrostreptomycin, etacrine acid and ATPh on the endocochlear potential in guinea-pigs depended on the dosage and means of administration."( [Relationship between the endocochlear potential and metabolism in the vascular stria of the inner ear].
Mazo, IL; Sagalovich, BM, 1977
)
0.26
" The dosage range of ethacrynic acid during which the interaction occurs is very narrow, while the dose range of kanamycin is very large."( Quantitative relationships of the ototoxic interaction of kanamycin and ethacrynic acid.
Brown, RT; Brummett, RE; Himes, DL, 1979
)
0.81
"The stability of liquid dosage forms of ethacrynic acid (1 mg/ml), indomethacin (2 mg/ml), methyldopate hydrochloride (25 mg/ml), prednisone (0."( Stability of pediatric liquid dosage forms of ethacrynic acid, indomethacin, methyldopate hydrochloride, prednisone and spironolactone.
Das Gupta, V; Ghanekar, AG; Gibbs, CW, 1978
)
0.78
" The maximum depression of the EP (reduction to -30 to -40 mV) was obtained at a dosage of 30 mg/kg."( Reduction of the endocochlear potential by the new "loop" diuretic, bumetanide.
Ise, I; Kambayashi, J; Kawamoto, K; Kusakari, J,
)
0.13
" Furosemide and ethacrynic acid, when used at the recommended dosage (1 mg/kg), would probably not produce a significant increase in free bilirubin in most infants."( Displacement of bilirubin from human albumin by three diuretics.
Ahlfors, CE; Rasmussen, F; Wennberg, RP, 1977
)
0.6
" The prophylactic effect upon ototoxicity of the administration of dimercaptopropanol or of dividing up the daily dosage was examined."( [Ototoxicity of the aminoglycoside antibiotics (author's transl)].
Federspil, P, 1976
)
0.26
" The maximum negativity of the AEP was significantly greater at a dosage of 100 mg/kg of EA than during ischemia."( Effects of anoxia and ethacrynic acid upon ampullar endolymphatic potential and upon high energy phosphates in ampullar wall.
Kusakari, J; Thalmann, R, 1976
)
0.57
" Addition of ethacrynic acid (3 micrograms ml-1) to treatment of the cell lines with melphalan or with cisplatin did not alter the dose-response curves to these agents."( A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines.
Rhodes, T; Twentyman, PR, 1992
)
1.04
" Comparison of dose-response curves for shift and block imposed by the inhibitor, indicate two different sites within the channel which interact with the ligand."( Identification and modulation of a voltage-dependent anion channel in the plasma membrane of guard cells by high-affinity ligands.
al-Awqati, Q; Hedrich, R; Landry, DW; Marten, I; Redhead, C; Zeilinger, C, 1992
)
0.28
"7 X 10(-4) M) doses or EA solvent (control) for 30 min, and dose-response curves were performed for GTN (10(-9) to 10(-5) M)."( Ethacrynic acid: acute hemodynamic effects and influence on the in vivo and in vitro response to nitroglycerin in the dog.
Abdollah, H; Armstrong, PW; Moffat, JA; Rollwage, D,
)
1.57
"A selective difference spectrophotometric procedure is described for the assay of ethacrynic acid (a diuretic drug) in pharmaceutical dosage forms."( Determination of ethacrynic acid in pharmaceutical formulations by difference ultraviolet spectrophotometry after derivatisation with N-acetylcysteine.
Bonazzi, D; Cavrini, V; Di Pietra, AM; Gatti, R, 1989
)
0.84
" The inhibitory dose-response curve for gentamicin is logarithmic, while that for ethacrynic acid is linear."( Inhibitory effects of gentamicin and ethacrynic acid on mammalian microsomal protein synthesis.
Buss, WC; Kauten, R; Piatt, MK, 1985
)
0.77
" The method was used in stability studies of the drug in the solid state, in solution, and in dosage forms."( Liquid chromatographic analysis of ethacrynic acid and degradation products in pharmaceutical systems.
Collett, JH; Moore, WD; Yarwood, RJ, 1985
)
0.55
" The effects of furosemide on ATPase and on Na flux were dissociable on a dose-response curve."( Ouabain-uninhibited sodium transport in human erythrocytes. Evidence against a second pump.
Dunn, MJ, 1973
)
0.25
" This inhibitory effect of low concentrations of ethacrynic acid could be surmounted by high, supramaximal dosage levels of vasopressin."( Effects of ethacrynic acid on the isolated collecting tubule.
Abramow, M, 1974
)
0.9
" When ethacrynic acid was applied intravenously at a dosage of 50 mg/kg, and the endolymphatic potential allowed to decline to -10mV, no significant changes in cyclic AMP and ATP were seen."( Arguments against a mediating role of the adenylate cyclase--cyclic AMP system in the ototoxic action of loop diuretics.
Kobayashi, T; Thalmann, I; Thalmann, R, 1982
)
0.75
"In anesthetized dogs, sodium reabsorption in the kidney tubule was continuously reduced with increasing dosage of ethacrynic acid until 59% of the filtered load was excreted with 25 mg."( Ethacrynic acid inhibits transcellular NaCl reabsorption in dog kidneys in doses of 1 to 10 mg.kg-1 and proximal bicarbonate-dependent reabsorption at higher doses.
Hartmann, A; Kiil, F; Steen, PA, 1981
)
1.92
" Aortic strips from SHR previously dosed with captopril showed equivalent or greater contractile responses to potassium chloride (KCl) and NE, when compared with strips from untreated age-matched controls."( Effects of captopril on vascular reactivity of SHR in vivo and in vitro.
Antonaccio, MJ; Kotler, D; Rubin, B,
)
0.13
" No changes occurred in ATP, ADP or phosphocreatine levels or the lactate/pyruvate ratio in cortical biopsies, which was in agreement with the previously shown lack of effect on proximal tubular reabsorption at this dosage of ethacrynic acid."( Inhibition of mitochondrial function is not the diuretic mechanism of ethacrynic acid in the dog.
Gronert, GA; Milde, JH; Steen, PA, 1983
)
0.68
" Despite few, well-designed studies using this method of administration in clinical practice, pharmacodynamic concepts support continuous infusion over bolus administration, including decreased dosage requirements, improved diuretic response and few adverse effects."( Continuous infusion of loop diuretics in the critically ill: a review of the literature.
Danziger, LH; Martin, SJ, 1994
)
0.29
" After dosing horses intravenously with 5 mg ethacrynic acid per horse, the parent drug or its metabolites are detectable in urine for at least 8 hours."( Immunoassay detection of drugs in racing horses: detection of ethacrynic acid and bumetanide in equine urine by ELISA.
Blake, JW; Chang, SL; Goodman, JP; Henry, PA; Kwiatkowski, S; Stanley, S; Tai, HH; Watt, D; Wood, T; Woods, WE,
)
0.63
"Cellular contraction was observed with ethacrynic acid, colchicine, and vinblastine in the 10(-5) to 10(-4) M dosage range."( Microtubule disruption leads to cellular contraction in human trabecular meshwork cells.
Epstein, DL; Gills, JP; Roberts, BC, 1998
)
0.57
" Each compound was evaluated for cytotoxicity to construct dosing regimens in transfection studies."( Alpha,beta-unsaturated aldehydes increase glutathione S-transferase mRNA and protein: correlation with activation of the antioxidant response element.
Kroll, DJ; Luckey, SW; Petersen, DR; Tjalkens, RB, 1998
)
0.3
" On the one hand, doctors have expressed the need to formulate a rectal suppository dosage form from diuretic ethacrynic acid, which would add to the choice of treatment methods and thereby increase the possibilities of individual cure."( Solutol and cremophor products as new additives in suppository formulation.
Berkó, S; Erös, I; Regdon, G, 2002
)
0.53
"Although it is well known that ethacrynic acid (EA) can enhance gentamicin (GM) ototoxicity, there has been no systematic study of the relationship between dosing parameters and inner ear pathology."( Chinchilla models of selective cochlear hair cell loss.
Ding, D; Jiang, H; McFadden, SL; Salvi, RJ; Woo, JM, 2002
)
0.6
" Dose-response curves (s."( Interaction between metamizol and tramadol in a model of acute visceral pain in rats.
Planas, E; Pol, O; Poveda, R; Puig, MM; Romero, A; Sánchez, S, 2003
)
0.32
" From dose-response curves with Sf9 membrane vesicles, glutathionylcurcumin conjugates appeared to be less potent inhibitors of MRP1 and MRP2 than their parent compound curcumin."( Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin.
Boersma, MG; Cnubben, NH; Rietjens, IM; Spenkelink, B; Usta, M; van Bladeren, PJ; van der Velde, AE; van Zanden, JJ; Wortelboer, HM, 2003
)
0.32
" In the chinchilla, co-administration of GM and EA can produce hair cell lesions ranging from a small loss of outer hair cells (OHCs) in the base of the cochlea to complete destruction of all hair cells, depending on dosing parameters."( Time course of efferent fiber and spiral ganglion cell degeneration following complete hair cell loss in the chinchilla.
Ding, D; Jiang, H; McFadden, SL; Salvi, RJ, 2004
)
0.32
" Dosage or duration of aminoglycosides use did not relate to SNHL."( Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure.
Cheung, PY; Etches, PC; Peliowski, A; Robertson, CM; Tyebkhan, JM, 2006
)
0.33
" Three days' daily single 20 microl dosing with 3% SA12590 reduced IOP by 4 mmHg (p<0."( Effects of the new ethacrynic acid oxime derivative SA12590 on intraocular pressure in cats and monkeys.
Epstein, DL; Kirihara, T; Matsugi, T; Rao, PV; Shimazaki, A; Tajima, H, 2007
)
0.67
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
ion transport inhibitorA compound which inhibits the movement of an ion across an energy-transducing cell membrane.
EC 2.5.1.18 (glutathione transferase) inhibitorAn EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of a glutathione transferase (EC 2.5.1.18).
loop diureticA diuretic that acts on the ascending loop of Henle in the kidney.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
monocarboxylic acidAn oxoacid containing a single carboxy group.
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Ethacrynic Acid Action Pathway319

Protein Targets (117)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency17.74070.140911.194039.8107AID2451
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency35.48130.125919.1169125.8920AID2549
LuciferasePhotinus pyralis (common eastern firefly)Potency47.11140.007215.758889.3584AID1224835; AID588342
interleukin 8Homo sapiens (human)Potency66.82420.047349.480674.9780AID651758
Nrf2Homo sapiens (human)Potency3.54810.09208.222223.1093AID624171
thioredoxin reductaseRattus norvegicus (Norway rat)Potency29.88160.100020.879379.4328AID588453
WRNHomo sapiens (human)Potency2.66790.168331.2583100.0000AID651768
phosphopantetheinyl transferaseBacillus subtilisPotency29.00270.141337.9142100.0000AID1490
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency32.85653.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency41.88360.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency28.34470.173734.304761.8120AID1346859; AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency32.64270.004110.890331.5287AID504466
SMAD family member 3Homo sapiens (human)Potency28.34470.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency20.00780.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency18.31330.000714.592883.7951AID1259368; AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency14.43260.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency26.52110.000221.22318,912.5098AID1259243; AID1259247; AID588516; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
thioredoxin glutathione reductaseSchistosoma mansoniPotency35.48130.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency30.30010.00527.809829.0929AID588855
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency40.85190.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency26.96800.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency34.87050.00137.762544.6684AID2120; AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency42.88280.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency23.01030.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency32.51080.000417.946075.1148AID1346784; AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency56.23410.531815.435837.6858AID504845
isocitrate dehydrogenase 1, partialHomo sapiens (human)Potency50.11876.309627.099079.4328AID602179
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency3.98110.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency39.12070.000214.376460.0339AID588533; AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency43.05270.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency25.84880.000817.505159.3239AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency40.09560.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency16.49020.375827.485161.6524AID588526; AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency22.80100.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency33.59510.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743077; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency3.89020.01238.964839.8107AID1645842
67.9K proteinVaccinia virusPotency14.57910.00018.4406100.0000AID720579; AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency35.48630.001024.504861.6448AID588534; AID588535; AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency32.47430.001019.414170.9645AID588537; AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency30.17410.023723.228263.5986AID588541; AID743222; AID743223
caspase-3Homo sapiens (human)Potency40.85190.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency18.35640.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.36900.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency33.66750.016525.307841.3999AID602332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency2.64120.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency10.68220.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency54.55810.057821.109761.2679AID1159526
serine-protein kinase ATM isoform aHomo sapiens (human)Potency39.81070.707925.111941.2351AID485349
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency39.81070.316212.443531.6228AID902
cytochrome P450 2C9 precursorHomo sapiens (human)Potency0.63100.00636.904339.8107AID883
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency10.04490.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency39.81070.010039.53711,122.0200AID588547
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency14.58100.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency89.12513.548119.542744.6684AID743266
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency40.50620.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency54.09510.037617.082361.1927AID1259364
heat shock protein beta-1Homo sapiens (human)Potency22.20360.042027.378961.6448AID743210; AID743228
huntingtin isoform 2Homo sapiens (human)Potency5.62340.000618.41981,122.0200AID1688
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency44.66844.466824.832944.6684AID651749
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency17.43040.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency79.43280.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency79.43280.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency9.45630.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency4.46680.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency4.46680.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency4.46680.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency28.36270.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency19.05480.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency4.54790.005612.367736.1254AID624032
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency44.66840.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency17.78280.251215.843239.8107AID504327
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency6.04570.058010.694926.6086AID602310
lethal factor (plasmid)Bacillus anthracis str. A2012Potency11.07920.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency3.87010.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency12.58930.015812.3113615.5000AID1461
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency24.16340.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency3.89020.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency13.70600.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency24.16340.001551.739315,848.9004AID1259244
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency0.63100.00638.235039.8107AID883
Nuclear receptor ROR-gammaHomo sapiens (human)Potency37.57800.026622.448266.8242AID651802
Guanine nucleotide-binding protein GHomo sapiens (human)Potency39.81071.995325.532750.1187AID624288
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency68.10160.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency68.10160.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, GLUTATHIONE TRANSFERASE A1-1Homo sapiens (human)IC50 (µMol)10.000010.000010.000010.0000AID977608
Chain A, Glutathione S-transferase P1-1Homo sapiens (human)Ki11.500011.500011.500011.5000AID977610
Chain A, Glutathione S-transferase P1-1Homo sapiens (human)Ki11.500011.500011.500011.5000AID977610
Chain B, Glutathione S-transferase P1-1Homo sapiens (human)Ki11.500011.500011.500011.5000AID977610
perilipin-5Homo sapiens (human)IC50 (µMol)4.83200.98503.45659.4680AID504319
perilipin-1Homo sapiens (human)IC50 (µMol)4.19000.92503.30339.6190AID504317
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform aHomo sapiens (human)IC50 (µMol)4.51100.92503.58289.6190AID504317; AID504319
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)95.90000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Hematopoietic prostaglandin D synthaseHomo sapiens (human)IC50 (µMol)122.30000.07100.92223.8000AID442514
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Glutathione S-transferase A1Homo sapiens (human)IC50 (µMol)5.00005.00005.00005.0000AID266616
Glutathione S-transferase PHomo sapiens (human)IC50 (µMol)11.13330.05121.70194.0000AID1802949; AID266617; AID441756
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusKi375.00000.00753.23929.1100AID1804126
Replicase polyprotein 1abHuman coronavirus 229EKi375.00000.00000.73329.1100AID1804126
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusKi375.00000.00753.00839.1100AID1804126
60 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)8.50000.17004.559010.0000AID1594139
Dual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)IC50 (µMol)4.50000.00100.97984.5000AID1720282
10 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)8.50000.17004.559010.0000AID1594139
Glutathione S-transferase omega-1Homo sapiens (human)IC50 (µMol)25.00000.02801.60404.6000AID1384567
UDP-glucose 4-epimeraseHomo sapiens (human)IC50 (µMol)14.00000.01401.37133.6000AID276473
Thiosulfate sulfurtransferaseHomo sapiens (human)IC50 (µMol)100.00000.06003.96319.7000AID1594135
60 kDa chaperonin Escherichia coliIC50 (µMol)4.95000.03903.55529.8000AID1594140; AID1594141
10 kDa chaperonin Escherichia coliIC50 (µMol)4.95000.03903.55529.8000AID1594140; AID1594141
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)3.85002.41006.343310.0000AID1473739
14 kDa phosphohistidine phosphataseHomo sapiens (human)IC50 (µMol)18.30007.90007.90007.9000AID1852932
large T antigenBetapolyomavirus macacaeIC50 (µMol)100.00000.160024.9724100.0000AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (345)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin biosynthetic processHematopoietic prostaglandin D synthaseHomo sapiens (human)
prostaglandin metabolic processHematopoietic prostaglandin D synthaseHomo sapiens (human)
signal transductionHematopoietic prostaglandin D synthaseHomo sapiens (human)
locomotory behaviorHematopoietic prostaglandin D synthaseHomo sapiens (human)
negative regulation of male germ cell proliferationHematopoietic prostaglandin D synthaseHomo sapiens (human)
glutathione metabolic processHematopoietic prostaglandin D synthaseHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
glutathione metabolic processGlutathione S-transferase A1Homo sapiens (human)
prostaglandin metabolic processGlutathione S-transferase A1Homo sapiens (human)
glutathione metabolic processGlutathione S-transferase A1Homo sapiens (human)
epithelial cell differentiationGlutathione S-transferase A1Homo sapiens (human)
linoleic acid metabolic processGlutathione S-transferase A1Homo sapiens (human)
cellular oxidant detoxificationGlutathione S-transferase A1Homo sapiens (human)
glutathione derivative biosynthetic processGlutathione S-transferase A1Homo sapiens (human)
xenobiotic metabolic processGlutathione S-transferase A1Homo sapiens (human)
response to reactive oxygen speciesGlutathione S-transferase PHomo sapiens (human)
negative regulation of acute inflammatory responseGlutathione S-transferase PHomo sapiens (human)
negative regulation of protein kinase activityGlutathione S-transferase PHomo sapiens (human)
prostaglandin metabolic processGlutathione S-transferase PHomo sapiens (human)
glutathione metabolic processGlutathione S-transferase PHomo sapiens (human)
xenobiotic metabolic processGlutathione S-transferase PHomo sapiens (human)
central nervous system developmentGlutathione S-transferase PHomo sapiens (human)
negative regulation of biosynthetic processGlutathione S-transferase PHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayGlutathione S-transferase PHomo sapiens (human)
negative regulation of interleukin-1 beta productionGlutathione S-transferase PHomo sapiens (human)
negative regulation of tumor necrosis factor productionGlutathione S-transferase PHomo sapiens (human)
regulation of stress-activated MAPK cascadeGlutathione S-transferase PHomo sapiens (human)
negative regulation of stress-activated MAPK cascadeGlutathione S-transferase PHomo sapiens (human)
positive regulation of superoxide anion generationGlutathione S-transferase PHomo sapiens (human)
common myeloid progenitor cell proliferationGlutathione S-transferase PHomo sapiens (human)
nitric oxide storageGlutathione S-transferase PHomo sapiens (human)
negative regulation of apoptotic processGlutathione S-transferase PHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionGlutathione S-transferase PHomo sapiens (human)
negative regulation of MAP kinase activityGlutathione S-transferase PHomo sapiens (human)
negative regulation of MAPK cascadeGlutathione S-transferase PHomo sapiens (human)
negative regulation of JUN kinase activityGlutathione S-transferase PHomo sapiens (human)
linoleic acid metabolic processGlutathione S-transferase PHomo sapiens (human)
negative regulation of fibroblast proliferationGlutathione S-transferase PHomo sapiens (human)
hepoxilin biosynthetic processGlutathione S-transferase PHomo sapiens (human)
negative regulation of nitric-oxide synthase biosynthetic processGlutathione S-transferase PHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeGlutathione S-transferase PHomo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeGlutathione S-transferase PHomo sapiens (human)
negative regulation of leukocyte proliferationGlutathione S-transferase PHomo sapiens (human)
cellular response to lipopolysaccharideGlutathione S-transferase PHomo sapiens (human)
negative regulation of monocyte chemotactic protein-1 productionGlutathione S-transferase PHomo sapiens (human)
cellular oxidant detoxificationGlutathione S-transferase PHomo sapiens (human)
glutathione derivative biosynthetic processGlutathione S-transferase PHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayGlutathione S-transferase PHomo sapiens (human)
protein folding60 kDa chaperoninEscherichia coli K-12
response to radiation60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
virion assembly60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
protein refolding60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
adhesion of symbiont to host60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell60 kDa heat shock protein, mitochondrialHomo sapiens (human)
'de novo' protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to cold60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interferon-alpha production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-10 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-12 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-6 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein refolding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell proliferation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of macrophage activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isotype switching to IgG isotypes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein stabilization60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone-mediated protein complex assembly60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein maturation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
biological process involved in interaction with symbiont60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cellular response to interleukin-760 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein import into mitochondrial intermembrane space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial unfolded protein response60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apoptotic mitochondrial changes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
osteoblast differentiationDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of protein phosphorylationDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
response to ischemiaDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
apoptotic processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
response to xenobiotic stimulusDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
ovulation cycle processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
stress-activated protein kinase signaling cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of prostaglandin secretionDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
p38MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
signal transduction in response to DNA damageDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of apoptotic processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
regulation of cell cycleDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cardiac muscle contractionDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
bone developmentDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cellular response to sorbitolDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
negative regulation of cold-induced thermogenesisDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
regulation of signal transduction by p53 class mediatorDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
osteoblast differentiation10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process10 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein10 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone cofactor-dependent protein refolding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumGlutathione S-transferase omega-1Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionGlutathione S-transferase omega-1Homo sapiens (human)
positive regulation of skeletal muscle contraction by regulation of release of sequestered calcium ionGlutathione S-transferase omega-1Homo sapiens (human)
L-ascorbic acid metabolic processGlutathione S-transferase omega-1Homo sapiens (human)
xenobiotic catabolic processGlutathione S-transferase omega-1Homo sapiens (human)
negative regulation of ryanodine-sensitive calcium-release channel activityGlutathione S-transferase omega-1Homo sapiens (human)
positive regulation of ryanodine-sensitive calcium-release channel activityGlutathione S-transferase omega-1Homo sapiens (human)
cellular response to arsenic-containing substanceGlutathione S-transferase omega-1Homo sapiens (human)
cellular oxidant detoxificationGlutathione S-transferase omega-1Homo sapiens (human)
glutathione metabolic processGlutathione S-transferase omega-1Homo sapiens (human)
galactose catabolic processUDP-glucose 4-epimeraseHomo sapiens (human)
galactose catabolic process via UDP-galactoseUDP-glucose 4-epimeraseHomo sapiens (human)
sulfur amino acid catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
cyanate catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
epithelial cell differentiationThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA import into mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA transportThiosulfate sulfurtransferaseHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
protein dephosphorylation14 kDa phosphohistidine phosphataseHomo sapiens (human)
actin cytoskeleton organization14 kDa phosphohistidine phosphataseHomo sapiens (human)
peptidyl-histidine dephosphorylation14 kDa phosphohistidine phosphataseHomo sapiens (human)
negative regulation of T cell receptor signaling pathway14 kDa phosphohistidine phosphataseHomo sapiens (human)
negative regulation of lyase activity14 kDa phosphohistidine phosphataseHomo sapiens (human)
lamellipodium organization14 kDa phosphohistidine phosphataseHomo sapiens (human)
positive regulation of cell motility14 kDa phosphohistidine phosphataseHomo sapiens (human)
negative regulation of ATP citrate synthase activity14 kDa phosphohistidine phosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (132)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
magnesium ion bindingHematopoietic prostaglandin D synthaseHomo sapiens (human)
glutathione transferase activityHematopoietic prostaglandin D synthaseHomo sapiens (human)
prostaglandin-D synthase activityHematopoietic prostaglandin D synthaseHomo sapiens (human)
calcium ion bindingHematopoietic prostaglandin D synthaseHomo sapiens (human)
protein bindingHematopoietic prostaglandin D synthaseHomo sapiens (human)
protein homodimerization activityHematopoietic prostaglandin D synthaseHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
glutathione transferase activityGlutathione S-transferase A1Homo sapiens (human)
glutathione peroxidase activityGlutathione S-transferase A1Homo sapiens (human)
steroid delta-isomerase activityGlutathione S-transferase A1Homo sapiens (human)
fatty acid bindingGlutathione S-transferase A1Homo sapiens (human)
glutathione transferase activityGlutathione S-transferase PHomo sapiens (human)
glutathione peroxidase activityGlutathione S-transferase PHomo sapiens (human)
fatty acid bindingGlutathione S-transferase PHomo sapiens (human)
protein bindingGlutathione S-transferase PHomo sapiens (human)
JUN kinase bindingGlutathione S-transferase PHomo sapiens (human)
kinase regulator activityGlutathione S-transferase PHomo sapiens (human)
S-nitrosoglutathione bindingGlutathione S-transferase PHomo sapiens (human)
dinitrosyl-iron complex bindingGlutathione S-transferase PHomo sapiens (human)
nitric oxide bindingGlutathione S-transferase PHomo sapiens (human)
magnesium ion binding60 kDa chaperoninEscherichia coli K-12
protein binding60 kDa chaperoninEscherichia coli K-12
ATP binding60 kDa chaperoninEscherichia coli K-12
isomerase activity60 kDa chaperoninEscherichia coli K-12
ATP hydrolysis activity60 kDa chaperoninEscherichia coli K-12
identical protein binding60 kDa chaperoninEscherichia coli K-12
unfolded protein binding60 kDa chaperoninEscherichia coli K-12
ATP-dependent protein folding chaperone60 kDa chaperoninEscherichia coli K-12
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
lipopolysaccharide binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
p53 binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
DNA replication origin binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
single-stranded DNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
double-stranded RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
high-density lipoprotein particle binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isomerase activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP hydrolysis activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
enzyme binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ubiquitin protein ligase binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein A-I binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP-dependent protein folding chaperone60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein kinase bindingDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
RNA binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding chaperone10 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
metal ion binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
glutathione transferase activityGlutathione S-transferase omega-1Homo sapiens (human)
protein bindingGlutathione S-transferase omega-1Homo sapiens (human)
oxidoreductase activityGlutathione S-transferase omega-1Homo sapiens (human)
glutathione dehydrogenase (ascorbate) activityGlutathione S-transferase omega-1Homo sapiens (human)
methylarsonate reductase activityGlutathione S-transferase omega-1Homo sapiens (human)
UDP-N-acetylglucosamine 4-epimerase activityUDP-glucose 4-epimeraseHomo sapiens (human)
UDP-glucose 4-epimerase activityUDP-glucose 4-epimeraseHomo sapiens (human)
identical protein bindingUDP-glucose 4-epimeraseHomo sapiens (human)
protein homodimerization activityUDP-glucose 4-epimeraseHomo sapiens (human)
thiosulfate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
5S rRNA bindingThiosulfate sulfurtransferaseHomo sapiens (human)
3-mercaptopyruvate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
protein binding14 kDa phosphohistidine phosphataseHomo sapiens (human)
calcium channel inhibitor activity14 kDa phosphohistidine phosphataseHomo sapiens (human)
transmembrane transporter binding14 kDa phosphohistidine phosphataseHomo sapiens (human)
actin filament binding14 kDa phosphohistidine phosphataseHomo sapiens (human)
protein histidine phosphatase activity14 kDa phosphohistidine phosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (68)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
nucleoplasmHematopoietic prostaglandin D synthaseHomo sapiens (human)
cytoplasmHematopoietic prostaglandin D synthaseHomo sapiens (human)
cytosolHematopoietic prostaglandin D synthaseHomo sapiens (human)
intracellular membrane-bounded organelleHematopoietic prostaglandin D synthaseHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolGlutathione S-transferase A1Homo sapiens (human)
extracellular exosomeGlutathione S-transferase A1Homo sapiens (human)
cytosolGlutathione S-transferase A1Homo sapiens (human)
extracellular regionGlutathione S-transferase PHomo sapiens (human)
extracellular spaceGlutathione S-transferase PHomo sapiens (human)
nucleusGlutathione S-transferase PHomo sapiens (human)
cytoplasmGlutathione S-transferase PHomo sapiens (human)
mitochondrionGlutathione S-transferase PHomo sapiens (human)
cytosolGlutathione S-transferase PHomo sapiens (human)
vesicleGlutathione S-transferase PHomo sapiens (human)
secretory granule lumenGlutathione S-transferase PHomo sapiens (human)
extracellular exosomeGlutathione S-transferase PHomo sapiens (human)
ficolin-1-rich granule lumenGlutathione S-transferase PHomo sapiens (human)
TRAF2-GSTP1 complexGlutathione S-transferase PHomo sapiens (human)
cytosolGlutathione S-transferase PHomo sapiens (human)
cytoplasm60 kDa chaperoninEscherichia coli K-12
cytosol60 kDa chaperoninEscherichia coli K-12
membrane60 kDa chaperoninEscherichia coli K-12
GroEL-GroES complex60 kDa chaperoninEscherichia coli K-12
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytoplasm60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrion60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
early endosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytosol60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
clathrin-coated pit60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cell surface60 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
coated vesicle60 kDa heat shock protein, mitochondrialHomo sapiens (human)
secretory granule60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm midpiece60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
migrasome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-containing complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
lipopolysaccharide receptor complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
cytoplasmDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
nucleoplasmDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cytoskeletonDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
mitochondrion10 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome10 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix10 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
cytoplasmGlutathione S-transferase omega-1Homo sapiens (human)
cytosolGlutathione S-transferase omega-1Homo sapiens (human)
extracellular exosomeGlutathione S-transferase omega-1Homo sapiens (human)
cytoplasmGlutathione S-transferase omega-1Homo sapiens (human)
cytosolUDP-glucose 4-epimeraseHomo sapiens (human)
cytosolUDP-glucose 4-epimeraseHomo sapiens (human)
extracellular spaceThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrial matrixThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nucleoplasm14 kDa phosphohistidine phosphataseHomo sapiens (human)
cytosol14 kDa phosphohistidine phosphataseHomo sapiens (human)
plasma membrane14 kDa phosphohistidine phosphataseHomo sapiens (human)
nuclear body14 kDa phosphohistidine phosphataseHomo sapiens (human)
leading edge of lamellipodium14 kDa phosphohistidine phosphataseHomo sapiens (human)
extracellular exosome14 kDa phosphohistidine phosphataseHomo sapiens (human)
cytosol14 kDa phosphohistidine phosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (356)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1327451Induction of apoptosis in human HL60 cells assessed as intact cells at 10 to 50 uM after 24 hrs by Annexin V/7AAD-dual staining based FACS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1145308Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine volume per 6 hrs at 1 mg/kg, po as gelatin capsules relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1327414Antiproliferative activity against human EPC after 24 to 72 hrs by MTS assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1145365Diuretic activity in mongrel dog assessed as urine volume per 6 hrs at 1 mg/kg, po (Rvb = 180 ml)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 2. (4-(3-Oxo-1-alkenyl)phenoxy)acetic acids.
AID1299039Cytotoxic activity against human H1299 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Potent anti-proliferative actions of a non-diuretic glucosamine derivative of ethacrynic acid.
AID1852938Covalent binding affinity to human PHPT1 C71A mutant expressed in Escherichia coli BL21 (DE3) assessed as covalent adduct formation at 10 equiv incubated for 1 hr by RP-HPLC based ESI-MS analysis2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Identification of a Target Site for Covalent Inhibition of Protein Phosphohistidine Phosphatase 1.
AID1145346Diuretic activity in mongrel dog assessed as excretion of potassium ion at 1 mg/kg, iv measured after 15 and 45 mins (Rvb = 46 to 28 uequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 2. (4-(3-Oxo-1-alkenyl)phenoxy)acetic acids.
AID1145307Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine Cl- level per 6 hrs at 1 mg/kg, po as gelatin capsules relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID26315Dissociation constant (pKa) (determined in 30% EtOH)1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Agents for the treatment of brain injury. 1. (Aryloxy)alkanoic acids.
AID1150360Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine volume per 6 hrs at 1 mg/kg, po as gelatin capsules (Rvb = 180 ml/6 hrs)1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 4. Various ((2-substituted and 2,2-disubstituted vinyl)aryloxy)acetic acids.
AID19555Compound was evaluated, at a concentration of 20 mM acid, for its ability to increase the solubility of sickle hemoglobin1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID464398Cytotoxicity against human MCF7/AZ cells assessed as reduction of cell viability after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Ethacrynic acid analogues lacking the alpha,beta-unsaturated carbonyl unit--potential anti-metastatic drugs.
AID1327413Antiproliferative activity against human HL60 cells after 24 to 72 hrs by MTS assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1327467Cell cycle arrest in human HL60 cells assessed as accumulation at sub G1 phase at 2.5 uM after 48 hrs by propidium iodide-staining based FACS analysis (Rvb = 1.4 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1327415Selectivity index, ratio of IC50 for human EPC to IC50 for human KB cells2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID195373Reduction of Astrocyte intracellular chloride concentration at 0.1 mM.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Effects of [(N-alkyl-1,3-dioxo-1H,3H-isoindolin-5-yl)oxy]alkanoic acids, [(N-alkyl-1-oxo-1H,3H-isoindolin-5-yl)oxy]butanoic acids, and related derivatives on chloride influx in primary astroglial cultures.
AID1594139Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1145286Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine K+ level at 10 mg/kg, iv measured after 15 to 45 mins post dose (Rvb = 5 to 104 uequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1145356Diuretic activity in mongrel dog assessed as urine volume at 1 mg/kg, iv measured after 15 and 45 mins (Rvb = 1 to 4 ml/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 2. (4-(3-Oxo-1-alkenyl)phenoxy)acetic acids.
AID1150570Diuretic activity in mongrel dog assessed as chloride level in excreted urine at 10 mg/kg, iv measured between 15 to 45 mins after dosage (Rvb = 3 to 64 uequiv/min)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 3. ((2-Nitro-1-alkenyl)aryloxy)acetic acids.
AID1145305Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine Na+ level per 6 hrs at 1 mg/kg, po as gelatin capsules relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID49599Mortality of animals recorded as the number of animals dead out of the total animals (39) taken for the study at dose 1 mg/kg1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Agents for the treatment of brain injury. 1. (Aryloxy)alkanoic acids.
AID701877Drug degradation in PBS buffer assessed as compound depletion at pH 7.4 after 30 mins by RP-LCMS analysis in presence of glutathione2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of a Plasmodium falciparum glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase inhibitor (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (ML276) that reduces paras
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1150362Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine K+ level per 6 hrs at 0.3 mg/kg, po as gelatin capsules (Rvb = 1 equiv/6 hrs)1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 4. Various ((2-substituted and 2,2-disubstituted vinyl)aryloxy)acetic acids.
AID1299048Cytotoxic activity against human HT1080 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Potent anti-proliferative actions of a non-diuretic glucosamine derivative of ethacrynic acid.
AID1145319Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine Cl- level per 6 hrs at 3 mg/kg, po as gelatin capsules relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1299042Cytotoxic activity against human SKBR3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Potent anti-proliferative actions of a non-diuretic glucosamine derivative of ethacrynic acid.
AID1299043Cytotoxic activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Potent anti-proliferative actions of a non-diuretic glucosamine derivative of ethacrynic acid.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID15984Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID294071Antiproliferative activity against human HL60 cells after 72 hrs2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
The synthesis of alpha,beta-unsaturated carbonyl derivatives with the ability to inhibit both glutathione S-transferase P1-1 activity and the proliferation of leukemia cells.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1145339Diuretic activity in mongrel dog assessed as excretion of sodium ion at 10 mg/kg, iv measured after 15 and 45 mins (Rvb = 13 to 54 uequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 2. (4-(3-Oxo-1-alkenyl)phenoxy)acetic acids.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1150566Diuretic activity in mongrel dog assessed as potassium level in excreted urine at 10 mg/kg, iv measured between 15 to 45 mins after dosage (Rvb = 7 to 63 uequiv/min)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 3. ((2-Nitro-1-alkenyl)aryloxy)acetic acids.
AID1896233Inhibition of human placenta glutathione S-transferase using GSH and CDNB as substrate preincubated for 2 mins followed by substrate addition and measured upto 6 mins in the presence of UV irradiation by spectrophotometric analysis2022Bioorganic & medicinal chemistry letters, Dec-01, Volume: 77Inhibition of glutathione S-transferases by photoactive calix[4]arene α-ketophosphonic acids.
AID90254Relative salidiuretic efficacy was scored in human; very marked1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Agents for the treatment of brain injury. 1. (Aryloxy)alkanoic acids.
AID1327466Cell cycle arrest in human HL60 cells assessed as accumulation at G2/M phase at 2.5 uM after 48 hrs by propidium iodide-staining based FACS analysis (Rvb = 2.2 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1327465Cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 2.5 uM after 48 hrs by propidium iodide-staining based FACS analysis (Rvb = 52.6 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID224546Diuretic activity in saline loaded mice, activity is expressed as the sodium present in urine as mean milli equivalent/kg per 5 hr at 64 mg/kg oral dose1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
[(6,7-Dichlorobenzo[b]thien-5-yl)oxy]acetic acids and 1,1-dioxides. 1. A structurally novel class of diuretics with hypotensive activity.
AID1145349Diuretic activity in mongrel dog assessed as excretion of chloride ion at 10 mg/kg, iv measured after 15 and 45 mins (Rvb = 4 to 64 uequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 2. (4-(3-Oxo-1-alkenyl)phenoxy)acetic acids.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1896232Inhibition of human placental glutathione S-transferase using GSH and CDNB as substrate preincubated for 5 mins followed by substrate addition and measured in the absence of UV irradiation by spectrophotometric analysis2022Bioorganic & medicinal chemistry letters, Dec-01, Volume: 77Inhibition of glutathione S-transferases by photoactive calix[4]arene α-ketophosphonic acids.
AID722556Inhibition of glutathione S-transferase pi in human Bel7402 cell lysates at 10 uM using CDNB and GSH as substrates by spectrophotometry2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis of spirolactone-type diterpenoid derivatives from kaurene-type oridonin with improved antiproliferative effects and their apoptosis-inducing activity in human hepatoma Bel-7402 cells.
AID1150358Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine K+ level per 6 hrs at 1 mg/kg, po as gelatin capsules (Rvb = 1 equiv/6 hrs)1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 4. Various ((2-substituted and 2,2-disubstituted vinyl)aryloxy)acetic acids.
AID214110Antimicrobial activity against Trichophyton mentagrophytes (ATCC 4807)1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Antimicrobial 3-methyleneflavanones.
AID1150581Diuretic activity in mongrel dog assessed as sodium level in excreted urine at 3 mg/kg, po measured for 6 hrs (Rvb = 2 mequivalents)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 3. ((2-Nitro-1-alkenyl)aryloxy)acetic acids.
AID1327422Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 24 hrs by MTS assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1299044Cytotoxic activity against human MDA-MB-468 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Potent anti-proliferative actions of a non-diuretic glucosamine derivative of ethacrynic acid.
AID1636363Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 2.3 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1852935Covalent inhibition of human PHPT1 expressed in Escherichia coli BL21 (DE3) assessed as increase in protein mass at 10 equiv incubated for 1 hr by RP-HPLC based ESI-MS analysis2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Identification of a Target Site for Covalent Inhibition of Protein Phosphohistidine Phosphatase 1.
AID1830590Antiproliferative activity against human BcaP37 cells assessed as cell viability incubated for 24 hrs by CCk8 assay2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Novel Electrophilic Warhead Targeting a Triple-Negative Breast Cancer Driver in Live Cells Revealed by "Inverse Drug Discovery".
AID681780TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Ethacrynic acid; 2000 uM) in Xenopus laevis oocytes1997The Journal of biological chemistry, Jul-25, Volume: 272, Issue:30
Expression cloning and characterization of a novel multispecific organic anion transporter.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID117496The diuretic activity of compound was measured after oral administration in saline loaded mice at 4 mg/kg after 5h.1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
[(3-aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series.
AID1327461Cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 2.5 uM after 24 hrs by propidium iodide-staining based FACS analysis (Rvb = 48.9 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1594137Inhibition of ATPase activity of Escherichia coli GroEL expressed in Escherichia coliDH5alpha incubated for 60 mins using ATP by spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1145292Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine volume at 1 mg/kg, iv measured after 15 to 45 mins post dose (Rvb = 1 to 4 ml/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID1145320Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine volume per 6 hrs at 3 mg/kg, po as gelatin capsules relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID276474Cytotoxicity against Trypanosoma brucei by Alamar blue assay2006Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22
Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.
AID1299047Cytotoxic activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Potent anti-proliferative actions of a non-diuretic glucosamine derivative of ethacrynic acid.
AID1327439Induction of apoptosis in human HL60 cells assessed as dead cells at 50 uM after 24 hrs by Annexin V/7AAD-dual staining based FACS analysis (Rvb = 0.1 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1327443Induction of apoptosis in human HL60 cells assessed as intact cells at 10 uM after 24 hrs by Annexin V/7AAD-dual staining based FACS analysis (Rvb = 91.6 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1720283Selectivity ratio of IC50 for MEK3 (unknown origin) to IC50 for MEK6 (unknown origin)2020Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13
Non-'classical' MEKs: A review of MEK3-7 inhibitors.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1830591Inhibition of recombinant GSTP1 (unknown origin) using GSH substrate2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Novel Electrophilic Warhead Targeting a Triple-Negative Breast Cancer Driver in Live Cells Revealed by "Inverse Drug Discovery".
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1852944Inhibition of human PHPT1 expressed in Escherichia coli BL21 (DE3) using pNPP as substrate assessed as Kinact/Ki by reciprocal analysis2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Identification of a Target Site for Covalent Inhibition of Protein Phosphohistidine Phosphatase 1.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1327418Antiproliferative activity against human HCT116 cells after 24 to 72 hrs by MTS assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID650625Inhibition of glutathione S-transferase pi in human HL60 cells using CDNB and GSH as substrates at 5 uM by spectrophotometry2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
The synthesis of ethacrynic acid thiazole derivatives as glutathione S-transferase pi inhibitors.
AID19558Compound was evaluated, at a concentration of 5 mM acid, for its ability to increase the solubility of sickle hemoglobin1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID1327463Cell cycle arrest in human HL60 cells assessed as accumulation at sub G1 phase at 2.5 uM after 24 hrs by propidium iodide-staining based FACS analysis (Rvb = 2.6 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1852939Covalent binding affinity to human PHPT1 C73A mutant expressed in Escherichia coli BL21 (DE3) assessed as covalent adduct formation at 10 equiv incubated for 1 hr by RP-HPLC based ESI-MS analysis2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Identification of a Target Site for Covalent Inhibition of Protein Phosphohistidine Phosphatase 1.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1709855Induction of apoptosis in human HeLa cells assessed as necrotic cells at 80 uM measured after 3 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.61%)2021ACS medicinal chemistry letters, May-13, Volume: 12, Issue:5
Induction of Apoptosis in Cancer Cells by Glutathione Transferase Inhibitor Mediated Hydrophobic Tagging Molecules.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID464397Antimigration against human MCF7/AZ cells at 10 to 25 uM after 24 hrs by wound healing assay2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Ethacrynic acid analogues lacking the alpha,beta-unsaturated carbonyl unit--potential anti-metastatic drugs.
AID234106Solubility ratio for sickle cell haemoglobin in presence and absence of compound1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Design, synthesis, and testing of potential antisickling agents. 7. Ethacrynic acid analogues.
AID1145354Diuretic activity in mongrel dog assessed as urine volume at 10 mg/kg, iv measured after 15 and 45 mins (Rvb = 1 to 2 ml/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 2. (4-(3-Oxo-1-alkenyl)phenoxy)acetic acids.
AID1150574Diuretic activity in mongrel dog assessed as volume of excreted urine at 10 mg/kg, iv measured between 15 to 45 mins after dosage (Rvb = 1 to 4 ml/min)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 3. ((2-Nitro-1-alkenyl)aryloxy)acetic acids.
AID140713Compound was tested for diuretic activity after oral administration of 64 mg/kg in saline-loaded mice (vehicle control value=0.3)1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Heterocyclic oxyacetic acid diuretics: indazole, benzisothiazole, and benzisothiazole 1,1-dioxide analogues of [[7-chloro-3-(2-fluorophenyl)-1,2-benzisoxazol-6-yl]oxy]acetic acid.
AID1594135Inhibition of native rhodanese (unknown origin) assessed as reduction in rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1150586Diuretic activity in mongrel dog assessed as potassium level in excreted urine at 3 mg/kg, po measured for 6 hrs (Rvb = 1 mequivalents)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 3. ((2-Nitro-1-alkenyl)aryloxy)acetic acids.
AID367683Inhibition of Wnt/beta-casein signaling in human SW480 cells by fluorimetry2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Amide derivatives of ethacrynic acid: synthesis and evaluation as antagonists of Wnt/beta-catenin signaling and CLL cell survival.
AID15233Distribution coefficient (D %) between octanol and buffer of pH 7.41982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Agents for the treatment of brain injury. 1. (Aryloxy)alkanoic acids.
AID1150591Diuretic activity in mongrel dog assessed as chloride level in excreted urine at 3 mg/kg, po measured for 6 hrs (Rvb = 2 mequivalents)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 3. ((2-Nitro-1-alkenyl)aryloxy)acetic acids.
AID1594143Selectivity index, ratio of IC50 for inhibition of native rhodanese (unknown origin) to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reducti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1327447Induction of apoptosis in human HL60 cells assessed as early apoptotic cells at 50 uM after 24 hrs by Annexin V/7AAD-dual staining based FACS analysis (Rvb = 7.7 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID37715Antimicrobial activity against Aspergillus niger (ATCC 16404)1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Antimicrobial 3-methyleneflavanones.
AID234107Solubility ratio of the sickle cell haemoglobin with compound to sickle cell haemoglobin with out compound at 7 mM1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Design, synthesis, and testing of potential antisickling agents. 7. Ethacrynic acid analogues.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID60412Diuretic activity was measured after oral administration in conscious water loaded dogs at 20 mg/kg after 1 hr1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
[(3-aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series.
AID1327434Induction of necrosis in human MRC5 SV2 cells assessed as increase in LDH release at 50 uM after 24 to 48 hrs by fluorescence assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID569159Inhibition of migration of human Hs578Ts(i)8 cells assessed as reduction in cell viability after 24 hrs2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Inhibitory effects of ethacrynic acid analogues lacking the α,β-unsaturated carbonyl unit and para-acylated phenols on human cancer cells.
AID45311Antimicrobial activity against Candida albicans (ATCC 10231, NRRL Y-477)1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Antimicrobial 3-methyleneflavanones.
AID1594136Selectivity index, ratio of IC50 for inhibition of native soluble pig heart MDH to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1145318Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine K+ level per 6 hrs at 3 mg/kg, po as gelatin capsules relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID1327460Cell cycle arrest in human HL60 cells assessed as accumulation at G0/G1 phase at 2.5 uM after 24 hrs by propidium iodide-staining based FACS analysis (Rvb = 43.5 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1709852Induction of apoptosis in human HeLa cells assessed as viable cells at 80 uM measured after 3 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 91.43%)2021ACS medicinal chemistry letters, May-13, Volume: 12, Issue:5
Induction of Apoptosis in Cancer Cells by Glutathione Transferase Inhibitor Mediated Hydrophobic Tagging Molecules.
AID1327426Inhibition of recombinant human GSTpie using 24 hrs pretreated human HL60 cells assessed as reduction in endogenous GSH content at 50 uM measured for 60 mins by fluorescence assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID19557Compound was evaluated, at a concentration of 40 mM acid, for its ability to increase the solubility of sickle hemoglobin1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID276473Inhibition of human GalE by HPAEC assay2006Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22
Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.
AID1299046Cytotoxic activity against human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Potent anti-proliferative actions of a non-diuretic glucosamine derivative of ethacrynic acid.
AID1852943Inhibition of human PHPT1 expressed in Escherichia coli BL21 (DE3) using pNPP as substrate assessed as inhibition constant by reciprocal analysis2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Identification of a Target Site for Covalent Inhibition of Protein Phosphohistidine Phosphatase 1.
AID1299045Cytotoxic activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Potent anti-proliferative actions of a non-diuretic glucosamine derivative of ethacrynic acid.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID234105Solubility ratio of the sickle cell haemoglobin with compound to sickle cell haemoglobin with out compound at 3 mM1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Design, synthesis, and testing of potential antisickling agents. 7. Ethacrynic acid analogues.
AID1852933Covalent inhibition of human PHPT1 expressed in Escherichia coli BL21 (DE3) using pNPP as substrate at 10 equiv preincubated for 60 mins by multimode microplate reader analysis2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Identification of a Target Site for Covalent Inhibition of Protein Phosphohistidine Phosphatase 1.
AID1150577Diuretic activity in mongrel dog assessed as sodium level in excreted urine at 1 mg/kg, po measured for 6 hrs (Rvb = 2 mequivalents)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 3. ((2-Nitro-1-alkenyl)aryloxy)acetic acids.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1327438Induction of apoptosis in human HL60 cells assessed as dead cells at 10 uM after 24 hrs by Annexin V/7AAD-dual staining based FACS analysis (Rvb = 0.1 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1150587Diuretic activity in mongrel dog assessed as chloride level in excreted urine at 1 mg/kg, po measured for 6 hrs (Rvb = 2 mequivalents)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 3. ((2-Nitro-1-alkenyl)aryloxy)acetic acids.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1852942Inhibition of human PHPT1 expressed in Escherichia coli BL21 (DE3) using pNPP as substrate assessed as Kinact by reciprocal analysis2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Identification of a Target Site for Covalent Inhibition of Protein Phosphohistidine Phosphatase 1.
AID569156Inhibition of migration of human C4-2B cells at 100 uM after 24 hrs2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Inhibitory effects of ethacrynic acid analogues lacking the α,β-unsaturated carbonyl unit and para-acylated phenols on human cancer cells.
AID1299041Cytotoxic activity against human SF188 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Potent anti-proliferative actions of a non-diuretic glucosamine derivative of ethacrynic acid.
AID1636521Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 12.1 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID441756Inhibition of GST P1-1 in human HL60 cell lysate2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Novel oxadiazole analogues derived from ethacrynic acid: design, synthesis, and structure-activity relationships in inhibiting the activity of glutathione S-transferase P1-1 and cancer cell proliferation.
AID22008Compound was evaluated, at a concentration of 10 mM acid, the solubility ratio is obtained by dividing the solubility of sickle hemoglobin (HbS) with the compound (grams per deciliter) by the solubility of the untreated sample (grams per deciliter)1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID276470Inhibition of Trypanosoma brucei GalE at 50 uM2006Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22
Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.
AID1327452Induction of apoptosis in human HL60 cells assessed as early apoptotic cells at 10 to 50 uM after 24 hrs by Annexin V/7AAD-dual staining based FACS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID52075Relative salidiuretic efficacy was scored in chimpanzee; very marked1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Agents for the treatment of brain injury. 1. (Aryloxy)alkanoic acids.
AID1852940Covalent binding affinity to human PHPT1 C73A mutant expressed in Escherichia coli BL21 (DE3) assessed as covalent adduct formation at 10 equiv incubated for 1 hr by LC-MS/MS analysis2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Identification of a Target Site for Covalent Inhibition of Protein Phosphohistidine Phosphatase 1.
AID187638Relative salidiuretic efficacy was scored in Rat; Marginal1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Agents for the treatment of brain injury. 1. (Aryloxy)alkanoic acids.
AID1709835Induction of GSTP1 degradation in human HeLa cells assessed as increase in c-Jun phosphorylation at 80 uM measured after 3 hrs by Western blot analysis2021ACS medicinal chemistry letters, May-13, Volume: 12, Issue:5
Induction of Apoptosis in Cancer Cells by Glutathione Transferase Inhibitor Mediated Hydrophobic Tagging Molecules.
AID1145359Diuretic activity in mongrel dog assessed as excretion of sodium ion per 6 hrs at 1 mg/kg, po (Rvb = 2 mequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 2. (4-(3-Oxo-1-alkenyl)phenoxy)acetic acids.
AID1594134Inhibition of native soluble pig heart MDH assessed as reduction in MDH enzyme activity using sodium mesoxalate as substrate and NADH by malachite green dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1852936Covalent inhibition of human PHPT1 C73A mutant expressed in Escherichia coli BL21 (DE3) using pNPP as substrate at 25 uM incubated for 1 hr by multimode microplate reader analysis2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Identification of a Target Site for Covalent Inhibition of Protein Phosphohistidine Phosphatase 1.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1150569Diuretic activity in mongrel dog assessed as chloride level in excreted urine at 1 mg/kg, iv measured between 15 to 45 mins after dosage (Rvb = 1 to 70 uequiv/min)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 3. ((2-Nitro-1-alkenyl)aryloxy)acetic acids.
AID1709853Induction of apoptosis in human HeLa cells assessed as early apoptotic cells at 80 uM measured after 3 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 4.37%)2021ACS medicinal chemistry letters, May-13, Volume: 12, Issue:5
Induction of Apoptosis in Cancer Cells by Glutathione Transferase Inhibitor Mediated Hydrophobic Tagging Molecules.
AID1327441Induction of apoptosis in human HL60 cells assessed as necrotic/late apoptotic cells at 50 uM after 24 hrs by Annexin V/7AAD-dual staining based FACS analysis (Rvb = 0.6 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1150361Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine Na+ level per 6 hrs at 0.3 mg/kg, po as gelatin capsules (Rvb = 2 equiv/6 hrs)1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 4. Various ((2-substituted and 2,2-disubstituted vinyl)aryloxy)acetic acids.
AID650626Inhibition of glutathione S-transferase pi in human HL60 cells using CDNB and GSH as substrates at 1 uM by spectrophotometry2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
The synthesis of ethacrynic acid thiazole derivatives as glutathione S-transferase pi inhibitors.
AID1145289Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine Na+ level at 1 mg/kg, iv measured after 15 to 45 mins post dose (Rvb = 4 to 82 uequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID276475Cytotoxicity against CHO-K1 cells by Alamar blue assay2006Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22
Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1327457Induction of apoptosis in human HL60 cells assessed as caspase 3/7 activation at 10 to 50 uM preincubated for 24 hrs after 180 mins by fluorescence assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID481939Inhibition of GST-mediated doxorubicin efflux in doxorubicin resistant human HepG2 cells uM by flow cytometry2010Journal of natural products, May-28, Volume: 73, Issue:5
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
AID442515Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation at 50 uM2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.
AID1852937Covalent binding affinity to human PHPT1 C69A mutant expressed in Escherichia coli BL21 (DE3) assessed as covalent adduct formation at 10 equiv incubated for 1 hr by RP-HPLC based ESI-MS analysis2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Identification of a Target Site for Covalent Inhibition of Protein Phosphohistidine Phosphatase 1.
AID1327412Antiproliferative activity against human KB cells after 24 to 72 hrs by MTS assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1145344Diuretic activity in mongrel dog assessed as excretion of potassium ion at 10 mg/kg, iv measured after 15 and 45 mins (Rvb = 16 to 37 uequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 2. (4-(3-Oxo-1-alkenyl)phenoxy)acetic acids.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1327444Induction of apoptosis in human HL60 cells assessed as intact cells at 50 uM after 24 hrs by Annexin V/7AAD-dual staining based FACS analysis (Rvb = 91.6 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1594138Selectivity index, ratio of IC50 for inhibition of native soluble pig heart MDH to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction i2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID1327425Induction of apoptosis in human HL60 cells assessed as necrotic/late apoptotic cells at 10 uM after 24 hrs by Annexin V/7AAD-dual staining based FACS analysis (Rvb = 0.6 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1327420Antiproliferative activity against human SKOV3 cells after 24 to 72 hrs by MTS assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1145291Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine Cl- level at 1 mg/kg, iv measured after 15 to 45 mins post dose (Rvb = 2 to 64 uequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID1754609Inhibition of Cl- channel in human monocytes assessed as inhibition of ATP-induced NLRP3 inflammasome-activation mediated IL-1beta release2021Bioorganic & medicinal chemistry letters, 08-15, Volume: 46Discovery of dronedarone and its analogues as NLRP3 inflammasome inhibitors with potent anti-inflammation activity.
AID117498The diuretic activity of compound was measured after oral administration in saline loaded mice at 64 mg/kg after 5h.1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
[(3-aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1594142Selectivity index, ratio of IC50 for inhibition of native rhodanese (unknown origin) to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduct2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID209089Antimicrobial activity against Streptococcus faecalis (ATCC 10541)1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Antimicrobial 3-methyleneflavanones.
AID1327462Cell cycle arrest in human HL60 cells assessed as accumulation at G2/M phase at 2.5 uM after 24 hrs by propidium iodide-staining based FACS analysis (Rvb = 5.1 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1150359Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine Cl- level per 6 hrs at 1 mg/kg, po as gelatin capsules (Rvb = 2 equiv/6 hrs)1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 4. Various ((2-substituted and 2,2-disubstituted vinyl)aryloxy)acetic acids.
AID19554Compound was evaluated, at a concentration of 10 mM acid, for its ability to increase the solubility of sickle hemoglobin1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID441757Growth inhibition of human HL60 cells by hemocytometry2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Novel oxadiazole analogues derived from ethacrynic acid: design, synthesis, and structure-activity relationships in inhibiting the activity of glutathione S-transferase P1-1 and cancer cell proliferation.
AID205808Antimicrobial activity against Staphylococcus aureus (ATCC 6538, NRRL B2747)1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Antimicrobial 3-methyleneflavanones.
AID1150562Diuretic activity in mongrel dog assessed as sodium level in excreted urine at 10 mg/kg, iv measured between 15 mins after dosage (Rvb = 5 to 66 uequiv/min)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 3. ((2-Nitro-1-alkenyl)aryloxy)acetic acids.
AID1594141Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1145321Half life of the compound in DMF-phosphate buffer at pH 7.4 at 25 degC assessed as SH binding in presence of mercaptoacetic acid1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID1327419Antiproliferative activity against human PC3 cells after 24 to 72 hrs by MTS assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1852932Inhibition of human PHPT1 expressed in Escherichia coli BL21 (DE3) using pNPP as substrate incubated for 1 hr by multimode microplate reader analysis2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Identification of a Target Site for Covalent Inhibition of Protein Phosphohistidine Phosphatase 1.
AID1720282Inhibition of MEK6 (unknown origin)2020Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13
Non-'classical' MEKs: A review of MEK3-7 inhibitors.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1327433Induction of necrosis in human HCT116 cells assessed as increase in LDH release 50 uM after 24 to 48 hrs by fluorescence assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID17335Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Substituted 5,6-dihydrofuro[3,2-f]-1,2-benzisoxazole-6-carboxylic acids: high-ceiling diuretics with uricosuric activity.
AID1327417Antiproliferative activity against human MCF7 cells after 24 to 72 hrs by MTS assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID276472Inhibition of Trypanosoma brucei GalE by HPAEC assay2006Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22
Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.
AID58923Relative salidiuretic efficacy was scored in dog; very marked1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Agents for the treatment of brain injury. 1. (Aryloxy)alkanoic acids.
AID1709834Induction of GSTP1 degradation in human HeLa cells assessed as increase in JNK phosphorylation at 80 uM measured after 3 hrs by Western blot analysis2021ACS medicinal chemistry letters, May-13, Volume: 12, Issue:5
Induction of Apoptosis in Cancer Cells by Glutathione Transferase Inhibitor Mediated Hydrophobic Tagging Molecules.
AID22010Compound was evaluated, at a concentration of 40 mM acid, the solubility ratio is obtained by dividing the solubility of sickle hemoglobin (HbS) with the compound (grams per deciliter) by the solubility of the untreated sample (grams per deciliter)1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1327421Antiproliferative activity against human OVCAR8 cells after 24 to 72 hrs by MTS assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1327450Induction of apoptosis in human HL60 cells assessed as necrotic/late apoptotic cells at 10 to 50 uM after 48 hrs by Annexin V/7AAD-dual staining based FACS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID266616Inhibition of GST A1-12006Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14
Bivalent inhibitors of glutathione S-transferase: the effect of spacer length on isozyme selectivity.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID569158Inhibition of migration of human C4-2B cells assessed as reduction in cell viability after 24 hrs2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Inhibitory effects of ethacrynic acid analogues lacking the α,β-unsaturated carbonyl unit and para-acylated phenols on human cancer cells.
AID58446Diuretic activity of compound measured in dog urine after intravenous injection of 5 mg/kg1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Design, synthesis, and testing of potential antisickling agents. 7. Ethacrynic acid analogues.
AID1327423Antiproliferative activity against human HL60 cells at 50 uM after 72 hrs by viacount-reagent based FACS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID569157Inhibition of migration of human Hs578Ts(i)8 cells at 100 uM after 24 hrs2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Inhibitory effects of ethacrynic acid analogues lacking the α,β-unsaturated carbonyl unit and para-acylated phenols on human cancer cells.
AID1145351Diuretic activity in mongrel dog assessed as excretion of chloride ion at 1 mg/kg, iv measured after 15 and 45 mins (Rvb = 10 to 26 uequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 2. (4-(3-Oxo-1-alkenyl)phenoxy)acetic acids.
AID1852934Covalent inhibition of human PHPT1 expressed in Escherichia coli BL21 (DE3) assessed as inhibition of dephosphorylation of histidine-phosphorylated BSA at 10 equiv preincubated for 1 hr followed by substrate addition and measured for 150 secs by Western b2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Identification of a Target Site for Covalent Inhibition of Protein Phosphohistidine Phosphatase 1.
AID442514Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID20828Na+ excretion mequiv/kg/kg in saline-loaded mice administered at a dose 10 ml/kg perorally1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Substituted 5,6-dihydrofuro[3,2-f]-1,2-benzisoxazole-6-carboxylic acids: high-ceiling diuretics with uricosuric activity.
AID1150357Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine Na+ level per 6 hrs at 1 mg/kg, po as gelatin capsules (Rvb = 2 equiv/6 hrs)1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 4. Various ((2-substituted and 2,2-disubstituted vinyl)aryloxy)acetic acids.
AID1145285Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine Na+ level at 10 mg/kg, iv measured after 15 to 45 mins post dose (Rvb = 4 to 82 uequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID781329pKa (acid-base dissociation constant) as determined by other workers2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1709854Induction of apoptosis in human HeLa cells assessed as late apoptotic cells at 80 uM measured after 3 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 3.59%)2021ACS medicinal chemistry letters, May-13, Volume: 12, Issue:5
Induction of Apoptosis in Cancer Cells by Glutathione Transferase Inhibitor Mediated Hydrophobic Tagging Molecules.
AID1636419Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 3.2 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID701902Drug degradation in PBS buffer assessed as compound depletion at pH 7.4 after 24 hrs by RP-LCMS analysis in presence of glutathione2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of a Plasmodium falciparum glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase inhibitor (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (ML276) that reduces paras
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1145361Diuretic activity in mongrel dog assessed as excretion of potassium ion per 6 hrs at 1 mg/kg, po (Rvb = 1 mequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 2. (4-(3-Oxo-1-alkenyl)phenoxy)acetic acids.
AID1327446Induction of apoptosis in human HL60 cells assessed as early apoptotic cells at 10 uM after 24 hrs by Annexin V/7AAD-dual staining based FACS analysis (Rvb = 7.7 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1150563Diuretic activity in mongrel dog assessed as sodium level in excreted urine at 1 mg/kg, iv measured between 15 mins after dosage (Rvb = 3 to 95 uequiv/min)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 3. ((2-Nitro-1-alkenyl)aryloxy)acetic acids.
AID266617Inhibition of GST P1-12006Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14
Bivalent inhibitors of glutathione S-transferase: the effect of spacer length on isozyme selectivity.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1327428Induction of necrosis in human HL60 cells assessed as increase in LDH release at 50 uM after 24 to 48 hrs by fluorescence assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1709838Induction of reactive oxygen species generation in human HeLa cells at 80 uM measured after 3 hrs by DCFH-DA staining based fluorescence laser confocal microscopic analysis2021ACS medicinal chemistry letters, May-13, Volume: 12, Issue:5
Induction of Apoptosis in Cancer Cells by Glutathione Transferase Inhibitor Mediated Hydrophobic Tagging Molecules.
AID1145317Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine Na+ level per 6 hrs at 3 mg/kg, po as gelatin capsules relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID1327432Induction of necrosis in human KB cells assessed as increase in LDH release at 50 uM after 24 to 48 hrs by fluorescence assay2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID650627Growth inhibition of human HL60 cells after 72 hrs by trypan blue staining2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
The synthesis of ethacrynic acid thiazole derivatives as glutathione S-transferase pi inhibitors.
AID1720284Selectivity ratio of IC50 for MEK4 (unknown origin) to IC50 for MEK6 (unknown origin)2020Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13
Non-'classical' MEKs: A review of MEK3-7 inhibitors.
AID1145290Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine K+ level at 1 mg/kg, iv measured after 15 to 45 mins post dose (Rvb = 5 to 104 uequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID1150565Diuretic activity in mongrel dog assessed as potassium level in excreted urine at 1 mg/kg, iv measured between 15 to 45 mins after dosage (Rvb = 6 to 47 uequiv/min)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 3. ((2-Nitro-1-alkenyl)aryloxy)acetic acids.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID22011Compound was evaluated, at a concentration of 5 mM acid, the solubility ratio is obtained by dividing the solubility of sickle hemoglobin (HbS) with the compound (grams per deciliter) by the solubility of the untreated sample (grams per deciliter)1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID662999Half life in rat plasma at 6.3 MBq, iv by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Synthesis and evaluation of [18F]Fluorobutyl ethacrynic amide: a potential PET tracer for studying glutathione transferase.
AID701882Chemical stability in PBS buffer at pH 7.4 at 10 uM up to 18 hrs by RP-LCMS analysis in presence of glutathione2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Discovery of a Plasmodium falciparum glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase inhibitor (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (ML276) that reduces paras
AID1145341Diuretic activity in mongrel dog assessed as excretion of sodium ion at 1 mg/kg, iv measured after 15 and 45 mins (Rvb = 26 to 58 uequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 2. (4-(3-Oxo-1-alkenyl)phenoxy)acetic acids.
AID234108Solubility ratio of the sickle cell haemoglobin with compound to sickle cell haemoglobin with out compound at 9 mM1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Design, synthesis, and testing of potential antisickling agents. 7. Ethacrynic acid analogues.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1150573Diuretic activity in mongrel dog assessed as volume of excreted urine at 1 mg/kg, iv measured between 15 to 45 mins after dosage (Rvb = 1 to 4 ml/min)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 3. ((2-Nitro-1-alkenyl)aryloxy)acetic acids.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1150363Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine Cl- level per 6 hrs at 0.3 mg/kg, po as gelatin capsules (Rvb = 2 equiv/6 hrs)1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 4. Various ((2-substituted and 2,2-disubstituted vinyl)aryloxy)acetic acids.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1720286Selectivity ratio of IC50 for MEK1 (unknown origin) to IC50 for MEK6 (unknown origin)2020Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13
Non-'classical' MEKs: A review of MEK3-7 inhibitors.
AID1145306Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine K+ level per 6 hrs at 1 mg/kg, po as gelatin capsules relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID266618Selectivity for GST A1-1 over GST P1-12006Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14
Bivalent inhibitors of glutathione S-transferase: the effect of spacer length on isozyme selectivity.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1517970Inhibition of human FBPase expressed in Escherichia coli BL21 (DE3) at 500 uM using FBP as substrate incubated for 5 mins by malachite green dye based spectrophotometry relative to control2019European journal of medicinal chemistry, Dec-15, Volume: 184Discovery of novel allosteric site and covalent inhibitors of FBPase with potent hypoglycemic effects.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID16006Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID48338In vitro inhibition of HCO3- stimulated swelling in cat cerebrocortical tissue slice1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Agents for the treatment of brain injury. 1. (Aryloxy)alkanoic acids.
AID1150364Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine volume per 6 hrs at 0.3 mg/kg, po as gelatin capsules (Rvb = 180 ml/6 hrs)1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 4. Various ((2-substituted and 2,2-disubstituted vinyl)aryloxy)acetic acids.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID662998Cytotoxicity against human A549 cells2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Synthesis and evaluation of [18F]Fluorobutyl ethacrynic amide: a potential PET tracer for studying glutathione transferase.
AID1145287Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine Cl- level at 10 mg/kg, iv measured after 15 to 45 mins post dose (Rvb = 2 to 64 uequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID1327416Selectivity index, ratio of IC50 for human EPC to IC50 for human HL60 cells2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1896230Inhibition of equine liver glutathione S-transferase using GSH and CDNB as substrate preincubated for 5 mins followed by substrate addition and measured in the absence of UV irradiation by spectrophotometric analysis2022Bioorganic & medicinal chemistry letters, Dec-01, Volume: 77Inhibition of glutathione S-transferases by photoactive calix[4]arene α-ketophosphonic acids.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1145363Diuretic activity in mongrel dog assessed as excretion of chloride ion per 6 hrs at 1 mg/kg, po (Rvb = 2 mequiv/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 2. (4-(3-Oxo-1-alkenyl)phenoxy)acetic acids.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1720285Selectivity ratio of IC50 for MEK2 (unknown origin) to IC50 for MEK6 (unknown origin)2020Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13
Non-'classical' MEKs: A review of MEK3-7 inhibitors.
AID1145288Diuretic activity in mongrel dog anesthetized with sodium pentobarbital assessed as urine volume at 10 mg/kg, iv measured after 15 to 45 mins post dose (Rvb = 1 to 4 ml/min)1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 1. (Diacylvinylaryloxy)acetic acids.
AID1327464Cell cycle arrest in human HL60 cells assessed as accumulation at G0/G1 phase at 2.5 uM after 48 hrs by propidium iodide-staining based FACS analysis (Rvb = 43.8 %)2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID20829Na+ excretion mequiv/kg/kg in saline-loaded mice administered at a dose 10 ml/kg perorally* -significantly different from control(p<0.05) and Duncan's test1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Substituted 5,6-dihydrofuro[3,2-f]-1,2-benzisoxazole-6-carboxylic acids: high-ceiling diuretics with uricosuric activity.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1150582Diuretic activity in mongrel dog assessed as potassium level in excreted urine at 1 mg/kg, po measured for 6 hrs (Rvb = 1 mequivalents)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
(Vinylaryloxy)acetic acids. A new class of diuretic agents. 3. ((2-Nitro-1-alkenyl)aryloxy)acetic acids.
AID1896231Inhibition of equine liver glutathione S-transferase using GSH and CDNB as substrate preincubated for 2 mins followed by substrate addition and measured upto 6 mins in the presence of UV irradiation by spectrophotometric analysis2022Bioorganic & medicinal chemistry letters, Dec-01, Volume: 77Inhibition of glutathione S-transferases by photoactive calix[4]arene α-ketophosphonic acids.
AID1299037Toxic diuretic effect in 12 hrs fasted CD1 mouse assessed as increase in urine output at 10 mg/kg, ip measured 0 to 6 hrs post dose relative to untreated control2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Potent anti-proliferative actions of a non-diuretic glucosamine derivative of ethacrynic acid.
AID22009Compound was evaluated, at a concentration of 20 mM acid, the solubility ratio is obtained by dividing the solubility of sickle hemoglobin (HbS) with the compound (grams per deciliter) by the solubility of the untreated sample (grams per deciliter)1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID1594140Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID294070Inhibition of GSTP1-1 activity at 40 umol/L after 30 mins relative to control2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
The synthesis of alpha,beta-unsaturated carbonyl derivatives with the ability to inhibit both glutathione S-transferase P1-1 activity and the proliferation of leukemia cells.
AID1299040Cytotoxic activity against human GBM10 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12
Potent anti-proliferative actions of a non-diuretic glucosamine derivative of ethacrynic acid.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1327449Induction of apoptosis in human HL60 cells assessed as dead cells at 10 to 50 uM after 48 hrs by Annexin V/7AAD-dual staining based FACS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action.
AID1384567Inhibition of human GSTO1-1 by MMA (V) reductase assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Reviewing Hit Discovery Literature for Difficult Targets: Glutathione Transferase Omega-1 as an Example.
AID367682Cytotoxicity against human CLL cells after 48 hrs by MTT method2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Amide derivatives of ethacrynic acid: synthesis and evaluation as antagonists of Wnt/beta-catenin signaling and CLL cell survival.
AID16004Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB1995Structure (London, England : 1993), Jul-15, Volume: 3, Issue:7
Structural analysis of human alpha-class glutathione transferase A1-1 in the apo-form and in complexes with ethacrynic acid and its glutathione conjugate.
AID1811Experimentally measured binding affinity data derived from PDB1995Structure (London, England : 1993), Jul-15, Volume: 3, Issue:7
Structural analysis of human alpha-class glutathione transferase A1-1 in the apo-form and in complexes with ethacrynic acid and its glutathione conjugate.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1804126No assay is provided from Article 10.1021/acs.jmedchem.5b01461: \\An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.\\2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.
AID1802949GST Assay from Article 10.3109/14756366.2010.486793: \\Glutathione transferase from Plasmodium falciparum--interaction with malagashanine and selected plant natural products.\\2010Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 25, Issue:6
Glutathione transferase from Plasmodium falciparum--interaction with malagashanine and selected plant natural products.
AID1799694GST Inhibition Assay from Article 10.1080/14756360701546595: \\Modulation of Anopheles gambiae Epsilon glutathione transferase activity by plant natural products in vitro.\\2008Journal of enzyme inhibition and medicinal chemistry, Jun, Volume: 23, Issue:3
Modulation of Anopheles gambiae Epsilon glutathione transferase activity by plant natural products in vitro.
AID1811Experimentally measured binding affinity data derived from PDB1997Biochemistry, Jan-21, Volume: 36, Issue:3
The three-dimensional structure of the human Pi class glutathione transferase P1-1 in complex with the inhibitor ethacrynic acid and its glutathione conjugate.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1997Biochemistry, Jan-21, Volume: 36, Issue:3
The three-dimensional structure of the human Pi class glutathione transferase P1-1 in complex with the inhibitor ethacrynic acid and its glutathione conjugate.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,130)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901557 (73.10)18.7374
1990's271 (12.72)18.2507
2000's155 (7.28)29.6817
2010's119 (5.59)24.3611
2020's28 (1.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.32 (24.57)
Research Supply Index7.76 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index114.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials64 (2.79%)5.53%
Reviews117 (5.11%)6.00%
Case Studies35 (1.53%)4.05%
Observational0 (0.00%)0.25%
Other2,075 (90.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Novel Drug Delivery Technique for Glaucoma Patients [NCT02051946]Phase 1/Phase 29 participants (Actual)Interventional2014-05-31Completed
Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection [NCT02852564]Phase 112 participants (Actual)Interventional2016-08-31Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
Phase III Study of Furosemide Continuous Infusion Versus Ethacrynic Acid Continuous Infusion in Children Undergoing Cardiac Surgery: Randomized Double Blind Controlled Clinical Trial [NCT01628731]Phase 374 participants (Actual)Interventional2012-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]